Eyepoint Pharmaceuticals (NASDAQ:EYPT) Hits New 12-Month Low Following Analyst Downgrade

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) reached a new 52-week low on Monday after Jefferies Financial Group lowered their price target on the stock to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Eyepoint Pharmaceuticals traded as low as $3.95 and last traded at $4.87, with a volume of 52110886 shares trading hands. The stock had previously closed at $14.75.

A number of other equities analysts have also recently issued reports on EYPT. Royal Bank Of Canada lowered their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. Finally, Guggenheim reissued a “buy” rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, implying substantial upside from the reported trading level. Chardan Capital also reaffirmed its “buy” rating with a $65 target. Benzinga analyst ratings
• Positive Sentiment: EyePoint said DURAVYU showed potentially favorable treatment-burden, supplement-free-rate, safety, and anatomic-control results through Week 56. In an ad hoc analysis excluding an asymmetric group of patients with unrelated vision loss, the drug was non-inferior to aflibercept. EyePoint LUGANO trial announcement
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating, indicating that the firm has not changed its cautious view despite the wide range of analyst price targets. Benzinga JPMorgan rating
• Neutral Sentiment: The stock was briefly halted for pending news, highlighting the market significance of the clinical update. A second pivotal Phase 3 trial remains important for determining DURAVYU’s regulatory and commercial prospects.
• Negative Sentiment: DURAVYU failed to achieve the primary endpoint in the full LUGANO dataset, despite EyePoint’s explanation that a 4% asymmetric cohort of nine patients with unrelated vision loss affected the result. The failure raises uncertainty about the drug’s approval prospects and the value of EyePoint’s pipeline. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded Eyepoint from “overweight” to “neutral,” while reports described the stock as approaching multi-month lows following the wet AMD trial setback. MSN EyePoint trial coverage

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EYPT. California State Teachers Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 2,158.3% in the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares during the period. Commodore Capital LP acquired a new stake in Eyepoint Pharmaceuticals in the 1st quarter valued at about $36,414,000. Simplify Asset Management Inc. grew its holdings in Eyepoint Pharmaceuticals by 314.9% during the fourth quarter. Simplify Asset Management Inc. now owns 375,264 shares of the company’s stock worth $6,856,000 after purchasing an additional 284,824 shares during the period. Walleye Capital LLC bought a new position in Eyepoint Pharmaceuticals during the first quarter worth about $3,869,000. Finally, Vanguard Group Inc. increased its position in Eyepoint Pharmaceuticals by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock worth $88,100,000 after buying an additional 1,027,623 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $13.10 and a two-hundred day simple moving average of $13.62. The stock has a market cap of $419.84 million, a price-to-earnings ratio of -1.30 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. As a group, equities analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.6 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.